Compare GLP-1 Therapies in India

Branded Semaglutide vs Generic Semaglutide

Branded vs Generic Semaglutide in India — Same Molecule, Very Different Price

Branded semaglutide (Novo Nordisk’s Ozempic and Wegovy) and Indian generic semaglutide are the same active molecule. Since the patent expired in March 2026, DCGI-approved generics — Sundae, Semaglyn, Semasize, Noveltreat and others — deliver identical semaglutide from about ₹220 per weekly shot, 3–5× cheaper than branded. Both need a prescription. Branded still leads on the full 2.4 mg obesity dose and pen polish; generics win decisively on price.

Trulicity vs Ozempic

Trulicity vs Ozempic in India — Dulaglutide or Semaglutide?

Trulicity (dulaglutide) and Ozempic (semaglutide) are both once-weekly GLP-1 injections approved in India for type 2 diabetes. In SUSTAIN-7, the only head-to-head trial, semaglutide lowered HbA1c and body weight more at each dose pairing tested. In India Ozempic is also cheaper — ₹5,660–9,100 a month versus about ₹11,300 for Trulicity — and generic semaglutide costs less again.

Ozempic vs Wegovy

Ozempic vs Wegovy in India — Which One Do You Actually Need?

Both are Novo Nordisk’s semaglutide and pharmacologically identical, but they are NOT interchangeable in India. Ozempic is DCGI-approved for type 2 diabetes (max weekly dose 2 mg), Wegovy is approved for chronic weight management (titrated up to 2.4 mg). If your goal is weight loss without diabetes, Wegovy is the on-label choice. If you have T2D, Ozempic is on-label and often cheaper.

Mounjaro vs Wegovy

Mounjaro vs Wegovy in India — Which Loses More Weight?

Mounjaro (tirzepatide, Eli Lilly) and Wegovy (semaglutide, Novo Nordisk) are the two highest-efficacy weight-loss injectables available in India. Mounjaro is a dual GIP/GLP-1 receptor agonist that produces ~22.5% body weight reduction at 15 mg over 72 weeks (SURMOUNT-1). Wegovy is a pure GLP-1 agonist producing ~14.9% at 2.4 mg over 68 weeks (STEP-1). Mounjaro generally wins on raw efficacy; Wegovy has longer real-world safety data.

Ozempic vs Mounjaro

Ozempic vs Mounjaro in India — For Diabetes and Weight

Both Ozempic (semaglutide) and Mounjaro (tirzepatide) are DCGI-approved for type 2 diabetes in India, and both also produce significant weight loss. Mounjaro’s dual GIP/GLP-1 mechanism delivers larger HbA1c reductions (1.9–2.6% vs Ozempic’s 1.4–1.8%) and roughly twice the weight loss at maximum dose. Ozempic is approximately half the price. The choice often comes down to diabetes control goals, weight-loss target, and budget.

Semaglutide vs Tirzepatide

Semaglutide vs Tirzepatide in India — Class-Level Comparison

Semaglutide is a single-agonist GLP-1 receptor drug; tirzepatide is a dual GIP/GLP-1 agonist. In India, semaglutide is available as Ozempic, Wegovy, Rybelsus, and 10+ Indian generic brands; tirzepatide is currently only available as Mounjaro. Tirzepatide produces ~50% more weight loss on average (~22% vs ~15% at maximum doses) but costs 3–5× more in India. The molecule choice is mechanism-vs-cost, with the brand choice within each class adding further variability.

Noveltreat vs Sematrinity

Noveltreat vs Sematrinity in India — Same Molecule, Different Indication

Noveltreat and Sematrinity are both Sun Pharma's Indian generic semaglutide — pharmacologically identical. The difference is the DCGI label: Noveltreat is approved for obesity (chronic weight management), Sematrinity for type 2 diabetes. Both are priced per weekly injection — Noveltreat ₹900–2,000/shot and Sematrinity ₹750–1,300/shot (roughly ₹3,000–8,000/month depending on dose). Pick Noveltreat if your goal is weight management at BMI ≥27.5; pick Sematrinity if you have T2D needing add-on glycaemic control.

Poviztra vs Wegovy

Poviztra vs Wegovy in India — Same Molecule, Different Distribution Strategy

Poviztra and Wegovy are pharmacologically identical — both contain Novo Nordisk's semaglutide for obesity. Wegovy is Novo Nordisk's direct India brand; Poviztra is distributed by Emcure under a Novo Nordisk partnership, targeted at tier-2 and tier-3 city access. After Emcure's April 2026 price cut, Poviztra runs ₹3,999–8,999/month vs Wegovy's ₹5,660–16,400/month. Same outcomes; different price points and distribution depth.